Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a
formidable challenge due to its immunosuppressive microenvironment, thereby confounding …

Gliomas are a diverse group of primary central nervous system tumors that affect both
children and adults. Recent studies have revealed a dynamic cross talk that occurs between …

Neoadjuvant immune-checkpoint blockade therapy only benefits a limited fraction of patients
with glioblastoma multiforme (GBM). Thus, targeting other immunomodulators on myeloid …

Importance Clinical outcomes for glioblastoma remain poor. Treatment with immune
checkpoint blockade has shown benefits in many cancer types. To our knowledge, data from …

T cells are critical effectors of cancer immunotherapies, but little is known about their gene
expression programs in diffuse gliomas. Here, we leverage single-cell RNA sequencing …

Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt
from central tolerance, can generate robust immune responses, and can function as bona …

Purpose: VEGF is upregulated in glioblastoma and may contribute to immunosuppression.
We performed a phase II study of pembrolizumab alone or with bevacizumab in recurrent …

Glioblastoma (GBM) is the most common primary brain tumor in adults an carries and carries
a terrible prognosis. The current regiment of surgical resection, radiation, and chemotherapy …

Background This review focuses on exosomes derived from various cancer cells. The review
discusses the possibility of differentiating macrophages in alternatively activated anti …

Immunotherapy is a promising area of therapy in patients with neuro-oncological
malignancies. However, early-phase studies show unique challenges associated with the …